Holzer Elad Y, Clark Tod A, Giuffre Jennifer L
From the Section of Plastic Surgery, Department of Surgery.
Department of Orthopedic, University of Manitoba, Winnipeg, Manitoba, Canada.
Ann Plast Surg. 2025 May 1;94(5):536-543. doi: 10.1097/SAP.0000000000004299. Epub 2025 Feb 13.
Hirayama disease (HD) is a rare, nonfamilial, monomelic amyotrophy in which patients present with muscle atrophy and weakness of the forearms and hands, either unilateral or bilateral, and without sensory loss. Current treatment guidelines describe the role of conservative treatments including cervical collars and neurotropic medications, as well as spinal surgery in select patients. Upper extremity surgery has not yet been incorporated into the treatment algorithm of HD. The objective of this study is twofold: to present a case series of HD patients treated with the incorporation of nerve and tendon transfers and joint fusions into the existing treatment algorithm and to perform a literature review of interventions.
Three cases (4 limbs) of HD treated surgically with nerve and tendon transfers and fusion are retrospectively reviewed. The subjective and objective results from surgery are reported. A literature review is performed on PubMed using "Hirayama disease" and "peripheral nerve surgery," "nerve transfer," "tendon transfer," "hand surgery," or "upper extremity surgery" as search terms to identify studies describing surgical treatment of HD outside of spinal surgery.
Three HD patients (4 limbs) were identified. The average age was 23 years old (range, 16-33 years). Patients presented with intrinsic muscle atrophy, hypothenar, and thenar atrophy. The disease had been present for an average of 6.5 years (range, 1.5-15 years) prior to referral. Two patients had unilateral involvement, whereas one had bilateral involvement. Two patients (3 limbs) were treated with an anterior interosseous (AIN) to ulnar motor nerve transfer, whereas a patient with delayed presentation underwent thumb metacarpophalangeal joint fusion and a Zancolli lasso to the fingers. All patients had subjective and objective improvements postoperation.The literature reveals three independent case reports of HD patients treated with upper extremity surgery. Two papers describe using a tendon transfer, whereas one paper describes an AIN to ulnar motor nerve transfer. All patients demonstrated functional improvements in follow-up.
HD can be successfully treated with a combination of upper extremity surgery and nerve transfers. To the authors' knowledge, this is the first literature review and the largest case series presenting such interventions in HD.
平山病(HD)是一种罕见的、非家族性的单肢肌萎缩症,患者表现为单侧或双侧前臂和手部肌肉萎缩及无力,且无感觉丧失。当前的治疗指南描述了保守治疗的作用,包括使用颈托和神经营养药物,以及对特定患者进行脊柱手术。上肢手术尚未纳入平山病的治疗方案。本研究的目的有两个:一是呈现一系列将神经和肌腱移位以及关节融合纳入现有治疗方案治疗的平山病患者病例;二是对相关干预措施进行文献综述。
回顾性分析3例(4条肢体)接受神经和肌腱移位及融合手术治疗的平山病患者。报告手术的主观和客观结果。在PubMed上进行文献综述,使用“平山病”和“周围神经手术”“神经移位”“肌腱移位”“手部手术”或“上肢手术”作为检索词,以识别描述脊柱手术以外的平山病手术治疗的研究。
确定了3例平山病患者(4条肢体)。平均年龄为23岁(范围16 - 33岁)。患者表现为固有肌萎缩、小鱼际肌和大鱼际肌萎缩。转诊前疾病平均存在6.5年(范围1.5 - 15年)。2例患者为单侧受累,1例为双侧受累。2例患者(3条肢体)接受了骨间前神经(AIN)至尺神经运动神经移位,而1例就诊延迟的患者接受了拇指掌指关节融合术和手指的赞科利套索手术。所有患者术后主观和客观情况均有改善。文献显示有3篇关于平山病患者接受上肢手术治疗的独立病例报告。2篇论文描述了使用肌腱移位,1篇论文描述了AIN至尺神经运动神经移位。所有患者在随访中均显示功能改善。
上肢手术和神经移位联合应用可成功治疗平山病。据作者所知,这是首次对平山病此类干预措施进行的文献综述及最大规模的病例系列报道。